Who
Tiffany Eul Davis Inglis
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Sera Prognostics.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $20K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Oct 2025
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $16K8,024 at $2.03 | filing |
| 10 Sep 2026filed 11 Sep 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $972486 at $2.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $972486 at $2.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $728362 at $2.01 | filing |
| 11 Jun 2026filed 15 Jun 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $728362 at $2.01 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —17,437 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —27,034 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —27,034 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —17,437 at $0.00 | filing |
| 15 Oct 2025filed 15 Oct 2025 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —107,000 at $0.00 | filing |
| 15 Oct 2025filed 15 Oct 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Reviewing Black Diamond Therapeutics (NASDAQ:BDTX) & Sera Prognostics (NASDAQ:SERA)SERA · tickerreport.com · 22 Oct 2026Head to Head Survey: Immunocore (NASDAQ:IMCR) and Sera Prognostics (NASDAQ:SERA)SERA · dailypolitical.com · 20 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewSERA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Tiffany Eul Davis Inglis; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.